Naltrexone for the treatment of amphetamine dependence: A randomized, placebo-controlled trial

American Journal of Psychiatry

Volumn 165, Issue 11, 2008, Pages 1442-1448

  Jayaram Lindström, Nitya ^b   Hammarberg, Anders ^b   Beck, Olof ^b   Franck, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; NALTREXONE;

ABSTINENCE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; WITHDRAWAL SYNDROME;

ADULT; AMPHETAMINE; AMPHETAMINE-RELATED DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; RECURRENCE; SUBSTANCE ABUSE DETECTION; SUBSTANCE WITHDRAWAL SYNDROME; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 55749116174     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2008.08020304     Document Type: Article

References (28)

1. United Nations Office on Drugs and Crime: World Drug Report 2005. Vienna, 2005
2. Swedish Council for Information on Alcohol and Other Drugs: Drug Trends in Sweden 2006. Report No 98. Stockholm, 2006
3. Dackis C, O'Brien C: Neurobiology of addiction: treatment and public policy ramifications. Nat Neurosci 2005; 8:1431-1436
4. Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P: Treatment for amphetamine dependence and abuse. Cochrane Database Syst Rev 2001(4):CD003022
5. Wise RA, Bozarth MA: A psychomotor stimulant theory of addiction. Psychol Rev 1987; 94:469-492
6. Llorens-Cortes C, Pollard H, Schwartz JC: Localization of opiate receptors in substantia nigra: evidence by lesion studies. Neurosci Lett 1979; 12:165-170
7. Moore RY, Bloom FE: Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. Annu Rev Neurosci 1978; 1:129-169
8. Johnson RP, Sar M, Stumpf WE: A topographic localization of enkephalin on the dopamine neurons of the rat substantia nigra and ventral tegmental area demonstrated by combined histofluorescence-immunocytochemistry. Brain Res 1980; 194:566-571
9. Unterwald EM: Regulation of opioid receptors by cocaine. Ann N Y Acad Sci 2001; 937:74-92
10. Azaryan AV, Coughlin LJ, Buzas B, Clock BJ, Cox BM: Effect of chronic cocaine treatment on mu- and delta-opioid receptor mRNA levels in dopaminergically innervated brain regions. J Neurochem 1996; 66:443-448
11. Gorelick DA, Kim YK, Bencherif B, Boyd SJ, Nelson R, Copersino M, Endres CJ, Dannals RF, Frost JJ: Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry 2005; 57:1573-1582
12. Jayaram-Lindstrom N, Wennberg P, Hurd YL, Franck J: Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. J Clin Psychopharmacol 2004; 24:665-669
13. Jayaram-Lindström N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J: Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology 2007; 33:1856-1863
14. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M: The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9:199-213
15. Sobell LC, Sobell MB: A technique for assessing self-reported alcohol consumption, in Measuring Alcohol Consumption. Edited by Litten RZ, Allen J. Totowa, NJ, Humana Press, 1992, pp 44-72
16. Tiffany ST, Singleton E, Haertzen CA, Henningfield JE: The development of a cocaine craving questionnaire. Drug Alcohol Depend 1993; 34:19-28
17. Andersson M, Gustavsson E, Stephanson N, Beck O: Direct injection LC-MS/MS method for identification and quantification of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in urine drug testing. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 861:22-28
18. Caroll KM: A Cognitive-Behavioral Approach: Treating Cocaine Addiction. NIH Publication Number 98-4308. Rockville, Md, National Institute on Drug Abuse, 1998
19. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H: Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 1994; 151:1463-1467
20. King AC, Volpicelli JR, Frazer A, O'Brien CP: Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl) 1997; 129:15-22
21. Lee MC, Wagner HN Jr, Tanada S, Frost JJ, Bice AN, Dannals RF: Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 1988; 29:1207-1211
22. Schmitz JM, Stotts AL, Rhoades HM, Grabowski J: Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav 2001; 26:167-180
23. McCaul ME, Wand GS, Eissenberg T, Rohde CA, Cheskin LJ: Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology 2000; 22:480-492
24. Croop RS, Faulkner EB, Labriola DF: The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. Arch Gen Psychiatry 1997; 54:1130-1135
25. Jayaram-Lindstrom N, Wennberg P, Beck O, Franck J: An open clinical trial of naltrexone for amphetamine dependence: compliance and tolerability. Nord J Psychiatry 2005; 59:167-171
26. Jaffe C, Bush KR, Straits-Troster K, Meredith C, Romwall L, Rosenbaum G, Cherrier M, Saxon AJ: A comparison of methamphetamine-dependent inpatients childhood attention deficit hyperactivity disorder symptomatology. J Addict Dis 2005; 24:133-152
27. Chiu CT, Ma T, Ho IK: Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone. Brain Res Bull 2005; 67:100-109
28. Anggadiredja K, Sakimura K, Hiranita T, Yamamoto T: Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: a possible mechanism for dissociation of primary and secondary reward. Brain Res 2004; 1021:272-276